Anti-Idiotypic MRNA Vaccine to Treat Autoimmune Disorders

Overview

Journal Vaccines (Basel)

Date 2024 Jan 26

PMID 38276668

Authors

Sarfaraz K Niazi

Affiliations

Soon will be listed here.

Abstract

The 80+ existing autoimmune disorders (ADs) affect billions with little prevention or treatment options, except for temporary symptomatic management, leading to enormous human suffering and a monumental financial burden. The autoantibodies formed in most ADs have been identified, allowing the development of novel anti-idiotypic antibodies to mute the autoantibodies using vaccines. Nucleoside vaccines have been successfully tested as antigen-specific immunotherapies (ASI), with mRNA technology offering multi-epitope targeting to mute multiple autoantibodies. This paper proposes using mRNA technology to produce anti-idiotypic antibodies with broad effectiveness in preventing and treating them. This paper delves into the state-of-the-art mRNA design strategies used to develop novel ASIs by selecting appropriate T cell and B cell epitopes to generate anti-idiotypic antibodies. The low cost and fast development of mRNA vaccines make this technology the most affordable for the global control of ADs.

Citing Articles

Tackling Infectious Diseases in the Caribbean and South America: Epidemiological Insights, Antibiotic Resistance, Associated Infectious Diseases in Immunological Disorders, Global Infection Response, and Experimental Anti-Idiotypic Vaccine....

Justiz-Vaillant A, Soodeen S, Gopaul D, Arozarena-Fundora R, Thompson R, Unakal C Microorganisms. 2025; 13(2).

PMID: 40005649 PMC: 11858333. DOI: 10.3390/microorganisms13020282.

Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery-A Humanitarian Cause.

Niazi S, Magoola M Int J Mol Sci. 2024; 25(23).

PMID: 39684504 PMC: 11641290. DOI: 10.3390/ijms252312797.

The role of autoantibodies in bridging obesity, aging, and immunosenescence.

Valentino T, Chen N, Makhijani P, Khan S, Winer S, Revelo X Immun Ageing. 2024; 21(1):85.

PMID: 39616399 PMC: 11607830. DOI: 10.1186/s12979-024-00489-2.

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.

Shi Y, Shi M, Wang Y, You J Signal Transduct Target Ther. 2024; 9(1):322.

PMID: 39543114 PMC: 11564800. DOI: 10.1038/s41392-024-02002-z.

Ophthalmologic Implications of Connective Tissue Diseases: A Comprehensive Review of Current Knowledge and Innovations.

Pawar Y, Thool A Cureus. 2024; 16(8):e67078.

PMID: 39286691 PMC: 11405085. DOI: 10.7759/cureus.67078.

References

Singh J, Malik D, Raina A . Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus. Vaccine. 2021; 39(7):1087-1095. PMC: 7796797. DOI: 10.1016/j.vaccine.2021.01.011. View

Pan S, Chia Y, Yee H, Fang Cheng A, Anjum C, Kenisi Y . Immunomodulatory potential of anti-idiotypic antibodies for the treatment of autoimmune diseases. Future Sci OA. 2021; 7(2):FSO648. PMC: 7787174. DOI: 10.2144/fsoa-2020-0142. View

Sahin U, Kariko K, Tureci O . mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov. 2014; 13(10):759-80. DOI: 10.1038/nrd4278. View

Findlay A, Goyal N, Mozaffar T . An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015; 51(5):638-56. DOI: 10.1002/mus.24566. View

Shoenfeld Y . The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med. 2004; 10(1):17-8. DOI: 10.1038/nm0104-17. View

Almaani S, Meara A, Rovin B . Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2016; 12(5):825-835. PMC: 5477208. DOI: 10.2215/CJN.05780616. View

Kaida K . Guillain-Barré Syndrome. Adv Exp Med Biol. 2019; 1190:323-331. DOI: 10.1007/978-981-32-9636-7_20. View

Moshkelgosha S, So P, Diaz-Cano S, Banga J . Preclinical models of Graves' disease and associated secondary complications. Curr Pharm Des. 2015; 21(18):2414-21. DOI: 10.2174/1381612821666150316121945. View

Cai X, Li J, Liu T, Brian O, Li J . Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design. Brief Funct Genomics. 2021; 20(5):289-303. PMC: 8194884. DOI: 10.1093/bfgp/elab027. View

10.

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

11.

Miyamoto D, Gordilho J, Santi C, Porro A . Epidermolysis bullosa acquisita. An Bras Dermatol. 2022; 97(4):409-423. PMC: 9263658. DOI: 10.1016/j.abd.2021.09.010. View

12.

Karlsen T, Folseraas T, Thorburn D, Vesterhus M . Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017; 67(6):1298-1323. DOI: 10.1016/j.jhep.2017.07.022. View

13.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

14.

Cole C, Vinay K, Borradori L, Amber K . Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms. Front Immunol. 2022; 13:912876. PMC: 9300999. DOI: 10.3389/fimmu.2022.912876. View

15.

Satokari R . High Intake of Sugar and the Balance between Pro- and Anti-Inflammatory Gut Bacteria. Nutrients. 2020; 12(5). PMC: 7284805. DOI: 10.3390/nu12051348. View

16.

Wardemann H, Hammersen J, Nussenzweig M . Human autoantibody silencing by immunoglobulin light chains. J Exp Med. 2004; 200(2):191-9. PMC: 2212019. DOI: 10.1084/jem.20040818. View

17.

Loehrer P, Zieger L, Simon O . Update on Paraneoplastic Cerebellar Degeneration. Brain Sci. 2021; 11(11). PMC: 8615604. DOI: 10.3390/brainsci11111414. View

18.

Melchionda V, Harman K . Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management. Clin Exp Dermatol. 2019; 44(7):740-746. DOI: 10.1111/ced.14041. View

19.

Jerram S, Leslie R . The Genetic Architecture of Type 1 Diabetes. Genes (Basel). 2017; 8(8). PMC: 5575672. DOI: 10.3390/genes8080209. View

20.

Gesualdo L, Di Leo V, Coppo R . The mucosal immune system and IgA nephropathy. Semin Immunopathol. 2021; 43(5):657-668. PMC: 8551125. DOI: 10.1007/s00281-021-00871-y. View